Marcus Ballinger

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• 2790P Machine learning classification of small cell lung cancer using plasma multiomics in IMPower133

  Annals of Oncology · 2025-09-01

• Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials

  Journal of Thoracic Oncology · 2025-08-05 · 5 citations

• Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

  The Lancet · 2025-06-01 · 66 citations

• Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

  Journal of Clinical Oncology · 2025-05-30 · 37 citations

• IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).

  Journal of Clinical Oncology · 2025-05-28 · 2 citations

• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

  Nature Medicine · 2025-05-16 · 31 citations

• 409P: IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients (pts) with stage II-IIIA PD-L1 TC ≥50% NSCLC

  Journal of Thoracic Oncology · 2025-03-01 · 1 citations

• MOSBY enables multi-omic inference and spatial biomarker discovery from whole slide images

  Scientific Reports · 2024-08-06 · 5 citations